Catalent, Inc. has completed the previously announced offer by Catalent Boston, Inc., a subsidiary of Catalent Pharma Solutions, Inc., to acquire all outstanding shares of Juniper Pharmaceuticals, Inc. for $11.50 per share. The acquisition expands Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and complements its integrated global clinical and commercial supply network. As a result of the merger, Juniper will become a wholly owned subsidiary of Catalent.
 
Juniper’s core businesses include Juniper Pharma Services, which provides fee-for-service pharmaceutical development and clinical trials manufacturing to clients, and its contract with Merck KGaA to supply CRINONE (progesterone gel) outside of the U.S.
 
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” said Jonathan Arnold, president, oral drug delivery, Catalent. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”